Prostate cancer detection: The impact of obesity on Asian men - Abstract

OBJECTIVE: To evaluate the impact of body mass index (BMI) on prostate cancer detection in biopsy-naive men presenting to a single tertiary hospital in Singapore.

MATERIALS AND METHODS: We retrospectively examined 458 men who underwent initial prostate biopsies between January 2012 and April 2014. Indications for biopsy were serum prostate-specific antigen level ≥4.0ng/ml, or digital rectal examination findings suspicious for malignancy, or both. Only men with serum prostate-specific antigen level < 20ng/ml were included. BMI categories were based on the World Health Organization recommendations (normal:< 25.0, overweight: 25.0-29.9, and obese: ≥30).

RESULTS: Of the 458 men included in our cohort, 125 (27.3%) men were positive for prostate cancer on biopsy, with 69 (15.1%) being clinically significant (Gleason ≥7). Men with BMI ≥25kg/m2 (41.7%) were younger (67.2 vs. 68.8y, P = 0.030), had larger prostates (45.5 vs. 40.1g, P = 0.014), and were more likely to have a positive biopsy finding (34.6% vs. 22.1%, P = 0.003). On multivariate analysis, being overweight or obese was associated with increased risk of having prostate cancer on biopsy (odds ratio [OR] = 2.61, 95% CI: 1.58-4.30, P< 0.001 and OR = 3.26, 95% CI: 1.37-7.73 P = 0.007, respectively). The same trend was observed for clinically significant cancers but not for clinically insignificant cancers (OR = 3.57, 95% CI: 1.87-6.82, P< 0.001 and OR = 3.86, 95% CI: 1.33-11.21, P = 0.013 for being overweight and obese, respectively).

CONCLUSION: Asian men with BMI ≥25kg/m2 are at greater risk of having a positive initial biopsy result. The BMI threshold (BMI ≥25kg/m2) for Asian men to be at increased risk of prostate cancer detection on initial biopsy is lower than that of Western populations (BMI ≥30kg/m2).

Written by:
Lee A, Chia SJ.   Are you the author?
Yong Loo Lin School of Medicine, National University of Singapore; Department of Urology, Tan Tock Seng Hospital.

Reference: Urol Oncol. 2015 Jun;33(6):266.e17-22.
doi: 10.1016/j.urolonc.2015.03.011

PubMed Abstract
PMID: 25865574 Prostate Cancer Section


Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.